Clinical Trials in Richmond, Texas
12 recruiting
Showing 1–12 of 12 trials
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled641 locationsNCT06935370
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
DepressionBipolar I Disorder
AbbVie380 enrolled78 locationsNCT04777357
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics280 enrolled175 locationsNCT05304767
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Bristol-Myers Squibb1,500 enrolled32 locationsNCT07379827
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD)
AbbVie315 enrolled52 locationsNCT06846320
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled18 locationsNCT06786624
Recruiting
Phase 2
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Difficult to Control Hypertension
E-Star BioTech, LLC120 enrolled29 locationsNCT06343298
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences600 enrolled18 locationsNCT06966401
Recruiting
Phase 2
Study of ALTO-300 in MDD
Major Depressive Disorder
Alto Neuroscience321 enrolled45 locationsNCT05922878
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Bipolar Depression
Intra-Cellular Therapies, Inc.384 enrolled59 locationsNCT06372964